Another mega-startup: China investors back TCR2's $125M cash round to fuel a preclinical assault on solid tumors
In yet another display of biotech’s bold fundraising environment right now, a Cambridge, MA-based startup with a handful of preclinical cancer drugs in its pipeline …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
